Your browser doesn't support javascript.
Placental growth factor level in plasma predicts COVID-19 severity and in-hospital mortality.
Smadja, David M; Philippe, Aurélien; Bory, Olivier; Gendron, Nicolas; Beauvais, Agathe; Gruest, Maxime; Peron, Nicolas; Khider, Lina; Guerin, Coralie L; Goudot, Guillaume; Levavasseur, Françoise; Duchemin, Jérome; Pene, Frédéric; Cheurfa, Cherifa; Szwebel, Tali-Anne; Sourdeau, Elise; Planquette, Benjamin; Hauw-Berlemont, Caroline; Hermann, Bertrand; Gaussem, Pascale; Samama, Charles-Marc; Mirault, Tristan; Terrier, Benjamin; Sanchez, Olivier; Rance, Bastien; Fontenay, Michaela; Diehl, Jean-Luc; Chocron, Richard.
  • Smadja DM; Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
  • Philippe A; Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Bory O; Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
  • Gendron N; Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Beauvais A; Université de Paris, Emergency Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Gruest M; Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
  • Peron N; Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Khider L; Université de Paris, Emergency Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Guerin CL; Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
  • Goudot G; Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Levavasseur F; Université de Paris, Intensive Care Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Duchemin J; Université de Paris, Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Pene F; Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
  • Cheurfa C; Curie Institute, Cytometry Department, Paris, France.
  • Szwebel TA; Université de Paris, Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Sourdeau E; Université de Paris, Institut Cochin, INSERM, Paris, France.
  • Planquette B; Hematology Department Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Hauw-Berlemont C; Université de Paris, Institut Cochin, INSERM, Paris, France.
  • Hermann B; Hematology Department Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Gaussem P; Internal Medicine Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Samama CM; Intensive Care Medicine and Reanimation Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Mirault T; Internal Medicine Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Terrier B; Emergency Unit, Hôpital Hôtel-Dieu, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Sanchez O; Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
  • Rance B; Respiratory Medicine Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Fontenay M; Université de Paris, Intensive Care Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Diehl JL; Université de Paris, Intensive Care Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
  • Chocron R; Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
J Thromb Haemost ; 19(7): 1823-1830, 2021 07.
Article in English | MEDLINE | ID: covidwho-1172713
Semantic information from SemMedBD (by NLM)
1. Placental Growth Factor PREDISPOSES COVID-19
Subject
Placental Growth Factor
Predicate
PREDISPOSES
Object
COVID-19
2. Plasma LOCATION_OF Placental Growth Factor
Subject
Plasma
Predicate
LOCATION_OF
Object
Placental Growth Factor
3. vascular inflammations COEXISTS_WITH Respiration Disorders
Subject
vascular inflammations
Predicate
COEXISTS_WITH
Object
Respiration Disorders
4. Patients LOCATION_OF Fibroblast Growth Factor 2
Subject
Patients
Predicate
LOCATION_OF
Object
Fibroblast Growth Factor 2
5. Patients LOCATION_OF PGF gene|PGF
Subject
Patients
Predicate
LOCATION_OF
Object
PGF gene|PGF
6. Patients LOCATION_OF VEGFA gene|VEGFA
Subject
Patients
Predicate
LOCATION_OF
Object
VEGFA gene|VEGFA
7. Epidermal cGVHD Score 2 PROCESS_OF Outpatients
Subject
Epidermal cGVHD Score 2
Predicate
PROCESS_OF
Object
Outpatients
8. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
9. Fibroblast Growth Factor 2 AUGMENTS Disease
Subject
Fibroblast Growth Factor 2
Predicate
AUGMENTS
Object
Disease
10. PGF gene|PGF AUGMENTS Disease
Subject
PGF gene|PGF
Predicate
AUGMENTS
Object
Disease
11. VEGFA gene|VEGFA AUGMENTS Disease
Subject
VEGFA gene|VEGFA
Predicate
AUGMENTS
Object
Disease
12. Placental Growth Factor PREDISPOSES COVID-19
Subject
Placental Growth Factor
Predicate
PREDISPOSES
Object
COVID-19
13. Plasma LOCATION_OF Placental Growth Factor
Subject
Plasma
Predicate
LOCATION_OF
Object
Placental Growth Factor
14. vascular inflammations COEXISTS_WITH Respiration Disorders
Subject
vascular inflammations
Predicate
COEXISTS_WITH
Object
Respiration Disorders
15. Patients LOCATION_OF Fibroblast Growth Factor 2
Subject
Patients
Predicate
LOCATION_OF
Object
Fibroblast Growth Factor 2
16. Patients LOCATION_OF PGF gene|PGF
Subject
Patients
Predicate
LOCATION_OF
Object
PGF gene|PGF
17. Patients LOCATION_OF VEGFA gene|VEGFA
Subject
Patients
Predicate
LOCATION_OF
Object
VEGFA gene|VEGFA
18. Epidermal cGVHD Score 2 PROCESS_OF Outpatients
Subject
Epidermal cGVHD Score 2
Predicate
PROCESS_OF
Object
Outpatients
19. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
20. Fibroblast Growth Factor 2 AUGMENTS Disease
Subject
Fibroblast Growth Factor 2
Predicate
AUGMENTS
Object
Disease
21. PGF gene|PGF AUGMENTS Disease
Subject
PGF gene|PGF
Predicate
AUGMENTS
Object
Disease
22. VEGFA gene|VEGFA AUGMENTS Disease
Subject
VEGFA gene|VEGFA
Predicate
AUGMENTS
Object
Disease
ABSTRACT

BACKGROUND:

Coronavirus disease 2019 (COVID-19) is a respiratory disease associated with vascular inflammation and endothelial injury.

OBJECTIVES:

To correlate circulating angiogenic markers vascular endothelial growth factor A (VEGF-A), placental growth factor (PlGF), and fibroblast growth factor 2 (FGF-2) to in-hospital mortality in COVID-19 adult patients.

METHODS:

Consecutive ambulatory and hospitalized patients with COVID-19 infection were enrolled. VEGF-A, PlGF, and FGF-2 were measured in each patient ≤48 h following admission.

RESULTS:

The study enrolled 237 patients with suspected COVID-19 208 patients had a positive diagnostic for COVID-19, of whom 23 were mild outpatients and 185 patients hospitalized after admission. Levels of VEGF-A, PlGF, and FGF-2 significantly increase with the severity of the disease (P < .001). Using a logistic regression model, we found a significant association between the increase of FGF-2 or PlGF and mortality (odds ratio [OR] 1.11, 95% confidence interval [CI; 1.07-1.16], P < .001 for FGF-2 and OR 1.07 95% CI [1.04-1.10], P < .001 for PlGF) while no association were found for VEGF-A levels. Receiver operating characteristic curve analysis was performed and we identified PlGF above 30 pg/ml as the best predictor of in-hospital mortality in COVID-19 patients. Survival analysis for PlGF confirmed its interest for in-hospital mortality prediction, by using a Kaplan-Meier survival curve (P = .001) and a Cox proportional hazard model adjusted to age, body mass index, D-dimer, and C-reactive protein (3.23 95% CI [1.29-8.11], P = .001).

CONCLUSION:

Angiogenic factor PlGF is a relevant predictive factor for in-hospital mortality in COVID-19 patients. More than a biomarker, we hypothesize that PlGF blocking strategies could be a new interesting therapeutic approach in COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vascular Endothelial Growth Factor A / COVID-19 Type of study: Prognostic study / Risk factors Limits: Adult / Female / Humans Language: English Journal: J Thromb Haemost Journal subject: Hematology Year: 2021 Document Type: Article Affiliation country: Jth.15339

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vascular Endothelial Growth Factor A / COVID-19 Type of study: Prognostic study / Risk factors Limits: Adult / Female / Humans Language: English Journal: J Thromb Haemost Journal subject: Hematology Year: 2021 Document Type: Article Affiliation country: Jth.15339